Here's why the Botanix (ASX:BOT) share price is slipping today

Botanix was busy over the fourth quarter, but its accomplishments aren't being well received by the market.

| More on:
Man slipping over on banana skin

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its latest quarterly report.

The cannabinoid-focused pharmaceutical dermatology company's quarter seemed to be a good one, but the market has reacted poorly.

Right now, the Botanix share price is 7.8 cents – 3.7% lower than its previous close.

Let's take a closer look at today's news from Botanix.

The news driving the Botanix share price

The Botanix share price is sliding despite the company's productive quarter that ended on 30 June. Let's take a look at what it was up to over the period.

Financial update

Botanix provided a brief financial update on its performance this quarter.  

The company stated it had $21.6 million in cash at the end of the quarter. That's enough to fund an estimated 12.8 future quarters.

During the quarter, it had net cash outflows of around $1.7 million and it invested roughly $1.2 million in research and development activities.

New drugs

The Botanix share price is dipping despite plenty of productivity over the 3 months ended 30 June.

Botanix launched the Phase 1B rosacea clinical study trial for its BTX 1702 product in June.

The trial is investigating the safety and tolerability of different concentrations of BTX 1702 over an 8-week period.

It's currently being hampered by COVID-19 restrictions. The company's looking at adding more trial sites to minimise the impact of potential future lockdowns.

Additionally, Botanix announced positive results from its BTX 1204A pilot study in canines with atopic dermatitis during the quarter.

The company said atopic dermatitis in canines is similar to that in humans and that the study's results are a good indication the treatment could be transferable.

Also, during the quarter Botanix launched the next phase of its BTX 1801 development program.

The program is aiming to help the nasal decolonisation of Staphylococcus aureus in haemodialysis patients.

It hopes BTX 1801 will help to prevent bloodstream infections in those undergoing haemodialysis, of which the company says there's an "urgent need and significant market opportunity".

Botanix Pharmaceuticals share price snapshot

The Botanix share price hasn't been having a great year so far on the ASX.

It is currently 39% lower than it was at the start of 2021. However, it has gained 58% since this time last year.

The company has a market capitalisation of around $78 million, with approximately 973 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 300 healthcare stock is surging 13% on FDA news

Here's what's getting investors excited today.

Read more »